All In Biotech

Drug Trial Radar · NCT06163326

A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo

A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSE-UP TITRATION, MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY, EFFICACY, AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO

Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 394 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

394

Actual

Start

Jan 19, 2024

Primary completion

Mar 31, 2027

Study completion Mar 31, 2027

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Dec 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV). Ritlecitinib is studied in patients with non-segmental vitiligo. Vitiligo is a chronic acquired depigmentation disorder characterized by well-defined pale white patches of skin. Non-segmental vitiligo is an autoimmune disorder and is the focus of this study. The study will show: * if the repigmentation (the recovery of pigmentation) achieved in study B7981040 (also called the "parent study") will stay the same or will further increase if you keep receiving the same study medicine (ritlecitinib 50 milligrams or placebo) * Or if more repigmentation can be achieved if you start receiving ritlecitinib 100 milligrams in this study * Or how long the repigmentation achieved during the parent study lasts if you start receiving placebo in this study. This study is seeking for participants who: * have non-segmental vitiligo (either active or stable) and * received ritlecitinib or placebo for 52 weeks in the parent study. A placebo looks exactly like the study capsule but does not contain any medicine in it. All participants in this study will receive the study medicine or placebo. The study medicine (ritlecitinib 50 milligrams or 100 milligrams) or placebo are capsules that are taken by mouth at home every day. On study visit days, you must take the medication at the study site, and not at home. Participants may receive the study medicine or placebo for up to 52 weeks. The study will look at the experiences of people receiving the study medicine. This will help see if ritlecitinib is better for treating vitiligo. Participants will be involved in this study for a maximum of 60 weeks. During this time, they will have 9 study visits during the study. Ritlecitinib 50 mg is an approved drug for the treatment of severe Alopecia Areata (a disease with similar abnormal changes in the body functions like vitiligo) in the US, EU and Japan. China, Great Britain and other market applications are pending.

Conditions

  • Vitiligo

Interventions

  • RitlecitinibDrug

    Ritlecitinib 50 mg capsule once daily

  • Ritlecitinib 100 mgDrug

    Ritlecitinib 100 mg capsule once daily

  • PlaceboDrug

    Matching capsule once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events (AEs) leading to discontinuationTime frame: Screening up to at least 30 days after last dose of study drug (week 52 or Early Termination)
  2. Incidence of clinically significant laboratory abnormalitiesTime frame: Screening up to at least 30 days after last dose of study drug (week 52 or Early Termination)

Locations

73 sites in 13 countries. Site status is shown where the registry gives one.

  • California Dermatology & Clinical Research Institute

    Encinitas, California

  • Marvel Clinical Research

    Huntington Beach, California

  • Wallace Medical Group, Inc

    Los Angeles, California

  • Encore Medical Research of Boynton Beach

    Boynton Beach, Florida

  • Skin Care Research

    Hollywood, Florida

  • ForCare Clinical Research

    Tampa, Florida

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana

  • DelRicht Research

    Baton Rouge, Louisiana

  • Lawrence J. Green, MD LLC

    Rockville, Maryland

  • University of Michigan

    Ann Arbor, Michigan

  • University of New Mexico Health Sciences Center

    Albuquerque, New Mexico

  • SUNY Downstate Health Sciences University

    Brooklyn, New York

  • University of North Carolina Medical Center

    Chapel Hill, North Carolina

  • Clinical & Translational Research Center (CTRC)

    Chapel Hill, North Carolina

  • Accellacare - Wilmington

    Wilmington, North Carolina

  • Wilmington Health, PLLC

    Wilmington, North Carolina

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Remington-Davis, Inc

    Columbus, Ohio

  • Medical University of South Carolina

    Charleston, South Carolina

  • Modern Research Associates, PLLC

    Dallas, Texas

  • Alpesh D. Desai, DO PLLC

    Houston, Texas

  • Austin Institute for Clinical Research

    Houston, Texas

  • The Skin Hospital

    Darlinghurst, New South Wales, Australia

  • North Eastern Health Specialists

    Campbelltown, South Australia, Australia

  • Skin Health Institute Inc.

    Carlton, Victoria, Australia

  • Dr Rodney Sinclair Pty Ltd

    East Melbourne, Victoria, Australia

  • The Alfred Hospital

    Melbourne, Victoria, Australia

  • UMHAT "Prof. Dr. Stoyan Kirkovich"AD

    Stara Zagora, Bulgaria

  • Medical Centre "Asklepiy"

    Dupnitsa, Kyustendil, Bulgaria

  • Diagnostic Consultative Center Aleksandrovska

    Sofia, Sofia (stolitsa), Bulgaria

  • Centre de Recherche Dermatologique du Quebec metropolitain

    Québec, Canada

  • Centre de Recherche Saint-Louis inc.

    Québec, Canada

  • Dermatology Research Institute

    Calgary, Alberta, Canada

  • CaRe Clinic

    Red Deer, Alberta, Canada

  • Lynderm Research Inc.

    Markham, Ontario, Canada

  • DermEdge Research

    Mississauga, Ontario, Canada

  • North York Research Inc

    Toronto, Ontario, Canada

  • Dermatology Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • The First Hospital of Wuhan

    Wuhan, Hubei, China

  • The First Hospital of China Medical University/Dermatology and STD Department

    Shenyang, Liaoning, China

Showing 40 of 73 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.